Project description:To investigate changes to eRNA transcripts in the presence and the absence of lapatinib in OE19 cells, we performed KAS-seq on OE19 cells treat with 500 nM lapatinib for 1 day.
Project description:To investigate enhancer activity in OE19 cells, we performed ATAC_STARR-seq and CUT&Tag_STARR-seq using antibodies against H3K27ac, BRD4 and MED1 .
Project description:To determine genes regulated by the transcriptional co-activator PPARGC1A in OAC cells and whether PPARGC1A activity is altered by lapatinib we performed RNA-seq on OE19 cells treated with non-targeting siRNA or siRNA targeting PPARGC1A. 24 hours post-transfection, cells were also treated with either DMSO or 500 nM lapatinib for 24 hours.
Project description:To investigate changes to gene expression associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.
Project description:To investigate changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.